Method for screening for possible presence of cancer

• US 6,022,692 A
• Filed: 04/29/1998
• Issued: 02/08/2000
• Est. Priority Date: 09/30/1994
• Status: Expired due to Term

• Current Assignee: Ludwig Institute for Cancer Research, Ltd.
• Original Assignee: Ludwig Institute for Cancer Research, Ltd.
• Inventors: Ikeda, Hideyuki, Boon-Falleur, Thierry, Coulie, Pierre
• Primary Examiner(s): BURKE, JULIE ELAINE
• Application Number:
  US09/069,637
• Time in Patent Office: 650 Days
• Field of Search: 536/23.1, 536/24.31, 536/24.3, 536/24.33, 435/6, 435/91.1
• US Class Current: 435/6.11
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: Y10S 530/828 Cancer

Abstract

A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.

Claims

1. A method for determining possible presence of cancer in a sample, comprising assaying said sample to determining expression of a gene, cDNA of which hybridizes to the complement of the nucleotide sequence set forth in SEQ ID NO:

1, under stringent conditions by contacting said sample with a nucleotide sequence which specifically hybridizes to mRNA or cDNA for said gene, wherein hybridization of said nucleotide sequence to said mRNA or cDNA is indicative of possible presence of cancer in said sample.

2. The method of claim 1, wherein said cDNA comprises the nucleotide sequence set forth in SEQ ID NO:

1, or SEQ ID NO;

2.

3. The method of claim 1, wherein said cancer is leukemia.

4. The method of claim 1, wherein said cancer is melanoma, lymphoma, renal carcinoma, sarcoma, or breast carcinoma.

5. The method of claim 1, wherein said cancer is lung squamous carcinoma or lung adenocarcinoma.

6. The method of claim 1, wherein said leukemia is acute leukemia.

7. The method of claim 1, wherein said cancer is naevi, neuroblastoma, head and neck squamous carcinoma, bladder cancer, or thyroid carcinoma.